SpectraCure AB (publ) OMXSTO:SPEC:
RECEIVES FINAL APPROVAL FROM GERMAN AUTHORITIES TO COMMENCE CLINICAL TRIAL
Spectracure Gets Approval To Commence Clinical Trial
Earlier from SpectraCure
- Spectracure Appoints Johannes Swartling As CEO
- Spectracure Reports Positive Results In Prostate Cancer Study
- SPEC: Clinical progress and new funding strengthen position despite ongoing losses
- SPEC: Q1 2025 saw continued losses and a planned rights issue as SpectraCure advances clinical studies
- SPEC: Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025
Later from SpectraCure
- Spectracure Q-Pro Patent Approved In Japan
- Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
- Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
- Spectracure Q3 Net Loss SEK 35 Mln
- Spectracure To Get SEK 31.3 Mln If All TO5 Warrants Utilized
Follow SpectraCure into a list and get an email when it puts out news.
Follow SpectraCure